drugset / Trial / NCT05088928
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care setting.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2022-05-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | — | — |
| Comparator | Rivaroxaban | Other / unclassified | — | — |